Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
HD-MAP typhoid vaccine
- Development stage
- Unknown
- Lead developer
- Vaxxas
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Transdermal
01
Overview
The HD-MAP typhoid vaccine is a second-generation typhoid conjugate vaccine (TCV) being developed by Vaxxas in collaboration with SK bioscience and the International Vaccine Institute (IVI). It utilizes Vaxxas' proprietary high-density microarray patch (HD-MAP) technology, a needle-free delivery system consisting of thousands of microscopic projections coated with a dried vaccine formulation. The active ingredient is SKYTyphoid, a typhoid conjugate vaccine antigen developed by SK bioscience. By delivering the vaccine directly to the dense population of immune cells just below the skin surface, the HD-MAP platform aims to enhance immune response and provide superior thermostability compared to traditional liquid vaccines, potentially eliminating the need for cold-chain storage and enabling easier administration in resource-limited settings.
- Other names
- Vaxxas HD-MAP typhoid vaccineHD-MAP SKYTyphoid
Beyond the preview
Go deeper on HD-MAP typhoid vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on HD-MAP typhoid vaccine.